Emergent BioSolutions Announces Approximately $140 Million in Contract Awards with the Government of Canada, Strengthening Canada’s Leadership in Health Preparedness

Emergent BioSolutions (NYSE: EBS) announced multiyear contracts and a contract modification with the Public Health Agency of Canada and Department of National Defence valued at up to approximately CAD 140 million.

Rhea-AI Summary

Emergent BioSolutions (NYSE: EBS) announced multiyear contracts and a contract modification with the Public Health Agency of Canada and Department of National Defence valued at up to approximately CAD 140 million. Emergent expects more than CAD 35 million in orders in 2026 and will supply four medical countermeasures, several made at its Health Canada–licensed facility to strengthen domestic production and surge capacity.

Committed annual procurements aim to ensure continuous production, rapid conversion to finished product, and long-term strategic stockpiling to support Canada's biodefence readiness.

Positive

• Contracts valued at approximately CAD 140 million over multiple years
• More than CAD 35 million in orders expected in 2026
• Four medical countermeasures committed for supply to Canadian authorities
• Health Canada–licensed domestic manufacturing strengthens sovereign production
• Committed annual procurements ensure continuous production and surge capacity

Negative

• None.

Argus Feb 27 session

-26.58% close to close Open Argus

Details

News Market Reaction – EBS

In the Feb 27 session, EBS declined 26.58%, reflecting a significant negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock dropped -26.6% in the session following this news. A negative reaction despite contract aw...

Analysis

The stock dropped -26.6% in the session following this news. A negative reaction despite contract awards up to $140 million CAD and more than $35M CAD of 2026 orders would fit a pattern where positive operational updates did not always translate into immediate gains. Prior FDA wins and debt reduction sometimes saw weak follow-through. In such cases, investors often focused on broader risk factors like execution, contract concentration, or timelines rather than headline value alone.

Key Figures

Canadian contracts value: $140 million CAD 2026 orders: $35M CAD+ Medical countermeasures: 4 products

Canadian contracts value

$140 million CAD

Total potential value of multiyear agreements with PHAC and DND

2026 orders

$35M CAD+

Orders Emergent will receive in 2026 under these agreements

Medical countermeasures

4 products

Number of medical countermeasures supplied under the agreements

Historical Context

5 past events · Latest: Feb 12

5 events

1. Feb 12

   FDA sNDA approval

   24h Move

   -0.2%

   FDA approved new OTC NARCAN nasal spray multipack configurations for broader distribution.

2. Feb 12

   Earnings date set

   24h Move

   -1.6%

   Announced timing of Q4 and full-year 2025 results and investor call.

3. Jan 14

   FDA device approval

   24h Move

   +3.0%

   FDA cleared NARCAN nasal spray carrying case to enhance everyday preparedness.

4. Jan 12

   Debt paydown

   24h Move

   -4.4%

   Announced voluntary $100M term-loan prepayment, reducing gross debt and improving flexibility.

5. Jan 08

   U.S. contract award

   24h Move

   -3.0%

   Received delivery order up to $21.5M to supply BioThrax to U.S. Department of War.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

medical countermeasures, drug substance, finished drug product, biodefence

4 terms

medical countermeasures medical

"to deliver critical medical countermeasures to support Canada’s biological threat preparedness"

Medical countermeasures are the vaccines, drugs, diagnostics, protective gear and other treatments used to prevent, detect or treat public health threats such as infectious disease outbreaks or chemical exposures. Think of them as a community’s medical toolkit or fire extinguisher for emergencies; they matter to investors because demand can spike quickly during crises, draw government contracts and funding, and influence a company’s revenue, regulatory risk and long-term valuation.

drug substance technical

"it produces druga0substancea0on a rolling basis with annual conversion to finished drug product"

The drug substance is the primary active ingredient in a medicine—the chemical or biological material that produces the intended therapeutic effect. Think of it like the main ingredient in a recipe: its availability, purity, cost to make, and the ability to produce it at scale affect regulatory approvals, manufacturing reliability and profit margins, so investors watch it as a key factor in a drug’s commercial prospects and risk profile.

finished drug product technical

"produces druga0substancea0on a rolling basis with annual conversion to finished drug product"

The finished drug product is the final, packaged medicine in its ready-to-use form — such as tablets, injections, creams or inhalers — that has been labeled, tested and cleared for distribution to patients or pharmacies. For investors, this matters because it represents the sellable item that generates revenue, carries regulatory approval and inventory value, and signals that manufacturing and quality controls are in place; think of it as a car fully assembled, inspected and ready to drive to market.

biodefence medical

"to strengthen domestic biodefence capacity. By strengthening our national stockpiles"

Biodefence is the set of tools, systems and policies designed to prevent, detect and respond to harmful biological threats such as infectious disease outbreaks or deliberate releases of pathogens. For investors it matters because biodefence drives demand for vaccines, diagnostics, protective gear, monitoring technologies and government contracts, much like a security system creates a market for alarms, locks and emergency services that protect homes and businesses.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WINNIPEG, Manitoba, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced a series of new contracts and a contract modification with the Public Health Agency of Canada (PHAC) and the Department of National Defence (DND) to deliver critical medical countermeasures to support Canada’s biological threat preparedness and response infrastructure. The multiyear agreements, valued at up to approximately $140 million CAD, build upon over a decade of collaboration between Emergent and Canada and reinforce Canada’s commitment to long-term readiness and advanced strategic stockpiling. Emergent will receive more than $35M million CAD in orders in 2026.

Under these agreements, Emergent will supply four medical countermeasures to protect against or treat biological threats. Committed annual procurements from Canadian authorities will help ensure continuous production and reliable supply of these critical countermeasures, as well as surge manufacturing capacity if required. Several of the medical countermeasures supplied under these agreements are manufactured at Emergent’s Health Canada–licensed facility in Canada, reinforcing domestic production capacity for critical health security assets, supporting highly skilled biomanufacturing jobs, and strengthening Canada’s capability to respond to biological threats.

Emergent specializes in developing, manufacturing and supplying medical countermeasures for national security and health preparedness through its network of USMCA-compliant facilities. Emergent offers partners an innovative supply model through which it produces drug substance on a rolling basis with annual conversion to finished drug product. This approach strengthens customer preparedness, supports secure supply chains and ensures that inventory can be rapidly converted and deployed as threats evolve. These products support how governments respond to emergencies and help protect the public from potential threats.

These procurements are an example of how defence and public health agencies can collectively ensure preparedness for the threats of today. This effort to stockpile critical medical countermeasures demonstrates Canada’s leadership in international health preparedness.

“Health security is an essential pillar of Canada’s national security. Protecting Canadians from biological threats requires the same vigilance, preparedness, and strategic foresight that we apply across our defence posture. Canada’s new Defence Industrial Strategy reinforces this commitment by identifying medical countermeasures as a key sovereign capability and by directing targeted investments to strengthen domestic biodefence capacity. By strengthening our national stockpiles and partnering with trusted Canadian suppliers, we continue to build a more resilient, self‑reliant health security ecosystem that protects our forces, our communities, and our sovereignty now and into the future,” said Major General Scott Malcolm, Surgeon General, Canadian Armed Forces.

“We are proud to continue our longstanding collaboration with the Public Health Agency of Canada and the Department of National Defence as they implement a forward looking, strategic preparedness framework, serving as a model of best practices in health preparedness,” said Dr. Chris Sinclair, vice president and head of global preparedness at Emergent. “Through innovative supply models, long-term public-private collaboration, and coordination across government agencies, Canada is able to strengthen its approach to public health preparedness and national security.”

About Emergent BioSolutions
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify. 

Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO

lindahlr@ebsi.com

Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Emergent BioSolutions (EBS) announce on February 26, 2026 about Canada contracts?

Emergent announced multiyear contracts and a modification with Canadian agencies valued up to CAD 140 million. According to the company, the agreements cover four medical countermeasures and include more than CAD 35 million in orders expected in 2026.

How much in orders will Emergent (EBS) receive from Canada in 2026?

Emergent will receive more than CAD 35 million in orders in 2026. According to the company, these near-term orders are part of multiyear procurements supporting continuous production and stockpiling.

Which products will Emergent (EBS) supply to Canada under the CAD 140M agreements?

Emergent will supply four medical countermeasures to protect against or treat biological threats. According to the company, several of these countermeasures are manufactured at its Health Canada–licensed facility in Canada.

What does the Emergent (EBS) contract mean for Canadian domestic manufacturing capability?

The contracts reinforce domestic production by using Emergent's Health Canada–licensed facility for several products. According to the company, this supports skilled biomanufacturing jobs and strengthens surge capacity for health security.

How do Emergent's (EBS) agreements support Canada's biodefence preparedness long term?

Committed annual procurements aim to ensure continuous drug substance production and rapid conversion to finished product. According to the company, this supply model supports secure supply chains and strategic stockpiling for evolving threats.